Medicare Enrolled

Dr. David Widman, M.D.

Rheumatology · Morristown, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
435 SOUTH ST, Morristown, NJ 07960
9735409198
In practice since 2006 (19 years)
NPI: 1821168816 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Widman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Widman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Widman

Dr. David Widman is a rheumatology specialist in Morristown, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Widman performed 45,974 Medicare services across 983 unique beneficiaries.

Between the years covered by Open Payments, Dr. Widman received a total of $8,616 from 39 pharmaceutical and/or device companies across 507 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Widman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 24% volume in NJ $8,616 industry payments

Medicare Practice Summary

Medicare Utilization ↗
45,974
Medicare services
Top 24% in NJ for rheumatology
983
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,420 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
41,600 $4 $10
Denosumab injection (Prolia/Xgeva) 2,280 $18 $34
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
510 $105 $199
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
470 $74 $161
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
275 $1 $2
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
204 $65 $160
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
159 $62 $189
Orthovisc intra-articular injection
An injection of hyaluronan or its derivative into a joint space to provide lubrication and cushioning.
79 $102 $750
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
55 $122 $275
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
55 $1 $30
New patient office visit, complex (60-74 min) 54 $189 $320
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
54 $48 $102
Injection, methylprednisolone acetate, 40 mg 36 $6 $39
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
33 $128 $365
Joint fluid aspiration or injection, small joint
Removal of fluid from a small joint or injection of medication into a small joint.
29 $42 $161
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
29 $148 $288
Joint fluid aspiration or injection, medium joint
Removal of fluid from a medium-sized joint or injection of medication into the joint space.
18 $53 $200
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
18 $9 $49
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
16 $83 $255
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.2% high complexity
97.2% medium
2.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$8,616
Total received (2018-2024)
Avg $1,231/year across 7 years
Top 23% in NJ for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
39
Companies
507
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,438 (86.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$770 (8.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$408 (4.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,736
2023
$1,290
2022
$426
2021
$41
2020
$417
2019
$2,934
2018
$1,772

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$473
Novartis Pharmaceuticals Corporation
$434
ABBVIE INC.
$198
Amgen Inc.
$167
Fresenius Kabi USA, LLC
$105
ANI Pharmaceuticals, Inc.
$87
UCB, Inc.
$80
GlaxoSmithKline, LLC.
$43
Radius Health, Inc.
$35
GENZYME CORPORATION
$34
Alexion Pharmaceuticals, Inc.
$29
AstraZeneca Pharmaceuticals LP
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
Lilly USA, LLC
$15
Top 3 companies account for 63.6% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,798
Novartis Pharmaceuticals Corporation
$928
Genentech USA, Inc.
$893
Amgen Inc.
$821
Janssen Scientific Affairs, LLC
$558
UCB, Inc.
$515
GlaxoSmithKline, LLC.
$489
PFIZER INC.
$366
AbbVie Inc.
$334
ABBVIE INC.
$253
AbbVie, Inc.
$206
GENZYME CORPORATION
$162
E.R. Squibb & Sons, L.L.C.
$130
Celgene Corporation
$108
Fresenius Kabi USA, LLC
$105
ANI Pharmaceuticals, Inc.
$87
Lilly USA, LLC
$81
Merck Sharp & Dohme Corporation
$80
Ferring Pharmaceuticals Inc.
$78
Horizon Therapeutics plc
$73
SANOFI-AVENTIS U.S. LLC
$67
Hikma Pharmaceuticals USA
$56
Horizon Pharma plc
$55
Radius Health, Inc.
$46
Ironwood Pharmaceuticals, Inc
$40
AstraZeneca Pharmaceuticals LP
$35
Bioventus LLC
$33
Boehringer Ingelheim Pharmaceuticals, Inc.
$30
Alexion Pharmaceuticals, Inc.
$29
Organon LLC
$28
FIDIA PHARMA USA INC.
$17
Kiniksa Pharmaceuticals, Ltd.
$15
Sobi, Inc
$15
Sebela Pharmaceuticals Inc.
$15
Flexion Therapeutics, Inc.
$14
Mylan Institutional Inc.
$14
Mallinckrodt LLC
$14
West-Ward Pharmaceuticals
$13
SANOFI PASTEUR INC.
$13
Top 3 companies account for 42.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · Cimzia · DUZALLO · Durolane · EUFLEXXA · EVENITY · Enbrel · FLUBLOK QUADRIVALENT · FORTEO · HUMIRA · HYALGAN · Hulio · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KRYSTEXXA · Kineret · LYRICA · Mitigare · OFEV · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · RENFLEXIS · RIDAURA · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYNVISC-ONE · TALTZ · TAVNEOS · TREMFYA · Tymlos · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Morristown?
Compare rheumatologists in the Morristown area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
112
Per 100K population
21.9
County median income
$134,929
Nearest hospital
GREYSTONE PARK PSYCHIATRIC HOSPITAL
4.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Widman is a mixed practice specialist, with above-average Medicare volume (top 24% in NJ), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Widman experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Widman performed 41,600 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Widman receive payments from pharmaceutical companies?
Yes. Dr. Widman received a total of $8,616 from 39 companies across 507 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Widman's costs compare to other rheumatologists in Morristown?
Dr. Widman's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Widman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →